Idiopathic Pulmonary Fibrosis Registry China Study
PORTRAY
1 other identifier
observational
800
1 country
1
Brief Summary
By mean of registry of newly diagnosed Chinese IPF patients from more than 15 sites, this study aims to build IPF prospective cohort, set up normative clinical database and a biological specimen bank, and examine the clinical characteristics of newly diagnosed Chinese IPF patients, as well as the nature history, prognosis, comorbidities and complications of IPF patients in China, the current treatment pattern, burden of illness, and quality of life of Chinese IPF patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 20, 2018
CompletedStudy Start
First participant enrolled
July 1, 2018
CompletedFirst Posted
Study publicly available on registry
September 11, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedSeptember 11, 2018
September 1, 2018
5 years
June 20, 2018
September 10, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Demographic and clinical characteristic of newly diagnosed Chinese IPF patients
Data analyses will be mainly descriptive.
up to 5 years
Secondary Outcomes (4)
Mortality in Chinese patients with IPF
up to 5 years
Cause of death in Chinese patients with IPF
up to 5 years
Progression-free survival in Chinese patients with IPF
up to 5 years
Description of the acute exacerbations in Chinese patients with IPF
up to 5 years
Eligibility Criteria
Chinese newly diagnosed IPF patients
You may qualify if:
- Physician diagnosed IPF during the last 3 months based upon ATS/ERS/JRS/ALAT guidelines 2011
- Aged 40 years and above at recruitment
- Willing and able to sign an informed consent
You may not qualify if:
- Lung transplantation expected within the next 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dai Huapinglead
Study Sites (1)
Huaping Dai
Beijing, Beijing Municipality, 100029, China
Related Publications (2)
Yang X, Wang H, Liu A, Ni Y, Wang J, Han Y, Xie B, Geng J, Ren Y, Zhang R, Liu M, Dai H. Evaluation of respiratory muscle dysfunction in patients with idiopathic pulmonary fibrosis: a prospective observational study with magnetic resonance imaging. BMC Pulm Med. 2025 Mar 14;25(1):118. doi: 10.1186/s12890-025-03572-6.
PMID: 40087606DERIVEDXie B, Ren Y, Geng J, He X, Ban C, Wang S, Jiang D, Luo S, Chen Q, Liu M, Feng R, Zhao L, Dai H, Wang C. Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study. BMJ Open. 2020 Nov 11;10(11):e036809. doi: 10.1136/bmjopen-2020-036809.
PMID: 33177132DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Deputy Director of Center for Respiratory Diseases
Study Record Dates
First Submitted
June 20, 2018
First Posted
September 11, 2018
Study Start
July 1, 2018
Primary Completion
June 30, 2023
Study Completion
June 30, 2023
Last Updated
September 11, 2018
Record last verified: 2018-09
Data Sharing
- IPD Sharing
- Will not share